Mobile

A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals’ thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biol...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-007043-27

A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals’ thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals thiomersal-reduced adjuvanted influenza vaccine in adults aged 65 years and above

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the immunological non-inferiority (in terms of HI antibody GMT) of the thiomersal-free AS25 adjuvanted influenza vaccine compared to the thiomersal-reduced AS25 adjuvanted influenza vaccine 21 days after vaccination in subjects aged >/= 65 years.

Critère d'inclusion

  • Immunization against influenza in male and female subjects aged >/= 65 years

Liens